TCM
ALDX icon

Tradewinds Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Tradewinds Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35
Closed – – 420
2022
Q2 		$0 Hold
35
– – ﹤0.01% 442
2022
Q1 		$0 Buy
+35
New +$139 ﹤0.01% 774

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Tradewinds Capital Management's ALDX Position: Q3 2022 in Review

Tradewinds Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 35 shares.

Tradewinds Capital Management first reported a position in ALDX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • Tradewinds Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 35 Aldeyra Therapeutics shares in Q3 2022.
  • Tradewinds Capital Management first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 2 quarters.
  • Tradewinds Capital Management's Aldeyra Therapeutics position peaked at $0 in Q2 2022.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Tradewinds Capital Management's 13F filing for Q3 2022, filed 18 Oct 2022.